Corcept Therapeutics Inc (NASDAQ: CORT) has seen a rise in its stock price by 12.12 in relation to its previous close of 61.53. However, the company has experienced a 10.75% gain in its stock price over the last five trading sessions. zacks.com reported 2025-01-29 that Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is It Worth Investing in Corcept Therapeutics Inc (NASDAQ: CORT) Right Now?
The price-to-earnings ratio for Corcept Therapeutics Inc (NASDAQ: CORT) is above average at 54.86x, Company’s 36-month beta value is 0.57.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CORT is 90.10M, and currently, short sellers hold a 18.04% ratio of that floaft. The average trading volume of CORT on January 30, 2025 was 916.86K shares.
CORT’s Market Performance
CORT’s stock has seen a 10.75% increase for the week, with a 31.48% rise in the past month and a 42.71% gain in the past quarter. The volatility ratio for the week is 4.62%, and the volatility levels for the past 30 days are at 4.17% for Corcept Therapeutics Inc The simple moving average for the past 20 days is 23.65% for CORT’s stock, with a 68.85% simple moving average for the past 200 days.
Analysts’ Opinion of CORT
Many brokerage firms have already submitted their reports for CORT stocks, with Truist repeating the rating for CORT by listing it as a “Buy.” The predicted price for CORT in the upcoming period, according to Truist is $38 based on the research report published on November 06, 2023 of the previous year 2023.
SVB Securities, on the other hand, stated in their research note that they expect to see CORT reach a price target of $25. The rating they have provided for CORT stocks is “Market Perform” according to the report published on April 11th, 2023.
Piper Sandler gave a rating of “Overweight” to CORT, setting the target price at $27 in the report published on April 04th of the previous year.
CORT Trading at 23.48% from the 50-Day Moving Average
After a stumble in the market that brought CORT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 9.53% of gains for the given period.
Volatility was left at 4.17%, however, over the last 30 days, the volatility rate increased by 4.62%, as shares surge +35.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.94% upper at present.
During the last 5 trading sessions, CORT rose by +10.77%, which changed the moving average for the period of 200-days by +193.49% in comparison to the 20-day moving average, which settled at $55.79. In addition, Corcept Therapeutics Inc saw 36.90% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CORT starting from Swisher Daniel N JR, who sale 2,200 shares at the price of $50.54 back on Jan 10 ’25. After this action, Swisher Daniel N JR now owns 0 shares of Corcept Therapeutics Inc, valued at $111,188 using the latest closing price.
Swisher Daniel N JR, the Director of Corcept Therapeutics Inc, proposed sale 2,200 shares at $50.54 during a trade that took place back on Jan 10 ’25, which means that Swisher Daniel N JR is holding shares at $111,188 based on the most recent closing price.
Stock Fundamentals for CORT
Current profitability levels for the company are sitting at:
- 0.23 for the present operating margin
- 0.98 for the gross margin
The net margin for Corcept Therapeutics Inc stands at 0.22. The total capital return value is set at 0.22. Equity return is now at value 25.53, with 20.38 for asset returns.
Based on Corcept Therapeutics Inc (CORT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 21.3. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 40.03.
Currently, EBITDA for the company is 108.32 million with net debt to EBITDA at -0.91. When we switch over and look at the enterprise to sales, we see a ratio of 11.29. The receivables turnover for the company is 10.53for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.70.
Conclusion
In a nutshell, Corcept Therapeutics Inc (CORT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
